


## Data Sheet

[WWW.UREIKO-CHEM.COM](http://WWW.UREIKO-CHEM.COM)

Global Supplier of Chemical Probes, Inhibitors & Agonists

**Product Name** : PCNA-I 1  
**Cat.No.** : URK-V2025  
**CAS No.** : 444930-42-1  
**Molecular Formula** :  $C_{17}H_{14}N_2O_2S$   
**Molecular Weight** : 310.37  
**Target** :  
**Solubility** :



### Biological Activity

PCNA-I1 is a small molecule inhibitor of proliferating cell nuclear antigen (PCNA), selectively binds to PCNA trimers with  $K_d$  of 0.14-0.41  $\mu M$ , inhibits the growth of tumor cells of various tissue types with  $IC_{50}$  of 0.2  $\mu M$ .

PCNA-I1 dose- and time-dependently reduced the chromatin-associated PCNA in cells, affected the growth of nontransformed cells at significantly higher concentrations ( $IC_{50}=1.6 \mu M$ ).

PCNA-I1 also dose-dependently reduced uptake of BrdU in PCNA-I1 treated cells, induced cancer cell arrest at both the S and G(2)/M phases.

PCNA-I1 induced DNA damage and apoptosis in both LNCaP (wild-type p53) and PC-3 cells (p53-null) and enhanced DNA damage and apoptosis triggered by cisplatin, also induced autophagy in PC-3 cells.

PCNA-I1 (i.v.) significantly retarded growth of LNCaP tumors of in nude mice without causing detectable effects on mouse body weight and hematology profiles.

### References

1. Tan Z, et al. Mol Pharmacol. 2012 Jun;81(6):811-9.
2. Dillehay KL, et al. Mol Cancer Ther. 2014 Dec;13(12):2817-26.

*Note: All products of Ureiko are only used for scientific research or drug certificate declaration, we do not provide products and services for any personal use!*

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

[JACK@UREIKO-CHEM.COM](mailto:JACK@UREIKO-CHEM.COM)